Gene · 5425
POLD2: DNA polymerase delta 2, accessory subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. POLD2: DNA polymerase delta 2, accessory subunit. Genes, record 5425. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5425
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P49005 | DNA polymerase delta subunit 2 | 469 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58441 | P49005 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 58444 | P49005 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11995 | P49005 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 6089 | P49005 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11995 | P49005 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 6089 | P49005 | Espacenet |
| EP 4464338 A2 | 2024-11-20 | 332 | P49005 | Espacenet |
| US 11680268 B2 | 2023-06-20 | 332 | P49005 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64934 | P49005 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 64936 | P49005 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ASPACYTARABINE | CHEMBL4297599 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CLOFARABINE | CHEMBL1750 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| CYTARABINE | CHEMBL803 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE | CHEMBL888 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| GEMCITABINE HYDROCHLORIDE | CHEMBL1637 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
| TROXACITABINE | CHEMBL359164 | DNA polymerase (alpha/delta/epsilon) inhibitor | INHIBITOR | ChEMBL |
Trials4,186
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | GEMCITABINE | PHASE3 | ClinicalTrials.gov | |
| NCT07604233 | CYTARABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07603557 | FLUDARABINE PHOSPHATE | PHASE2 | ClinicalTrials.gov | |
| NCT07602140 | GEMCITABINE | PHASE2 | ClinicalTrials.gov | |
| NCT07598318 | GEMCITABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07588360 | CYTARABINE | ClinicalTrials.gov | ||
| NCT07583888 | CYTARABINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07579195 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07575191 | GEMCITABINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07570849 | GEMCITABINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 4,186
See all 4,186 trialsNIH grants429
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | POLD2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30CA036727 | Buffett Cancer Center Support Grant | 3 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 3 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 2 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 2 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
| P30CA124435 | Stanford Cancer Institute | 2 | 2025 |
1 to 10 of 429Source NIH's project files
See all 429 nih grantsPapers485
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive analysis of POLD2 as a potential biomarker for modulating the immune microenvironment and predicting immunotherapy response in lung adenocarcinoma. | J Thorac Dis | 2026 | 42444900 | PubTator, text mining | PubMed |
| [Transcriptomic Profile of the Trastuzumab-Resistant Breast Cancer Cell Line BT-474]. | Mol Biol (Mosk) | 2025 | 41090333 | PubTator, text mining | PubMed |
| Chasing the Ghost Proteome in the Dark Matter. | Mol Cell Proteomics | 2025 | 41033461 | PubTator, text mining | PubMed |
| BOGO: A Proteome-Wide Gene Overexpression Platform for Discovering Rational Cancer Combination Therapies. | bioRxiv | 2025 | 40950237 | PubTator, text mining | PubMed |
| Using machine learning to discover DNA metabolism biomarkers that direct prostate cancer treatment. | Sci Rep | 2025 | 40681784 | PubTator, text mining | PubMed |
| Construction and validation of a prognostic model for glioma: an analysis based on mismatch repair-related genes and their correlation with clinicopathological features. | Transl Cancer Res | 2025 | 40530129 | PubTator, text mining | PubMed |
| The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication. | Transl Cancer Res | 2025 | 40224989 | PubTator, text mining | PubMed |
| ASO Author Reflections: Clinical and Biological Significance of POLD2 in Lung Adenocarcinoma. | Ann Surg Oncol | 2025 | 40126712 | PubTator, text mining | PubMed |
| DNA Polymerase Delta 2 Activates Cell Cycle in Lung Adenocarcinoma, Leading to High Malignancy and Poor Prognosis. | Ann Surg Oncol | 2025 | 40095310 | PubTator, text mining | PubMed |
| Development of the TP53 mutation associated hypopharyngeal squamous cell carcinoma prognostic model through bulk multi-omics sequencing and single-cell sequencing. | Braz J Otorhinolaryngol | 2025 | 39341197 | PubTator, text mining | PubMed |
1 to 10 of 485
See all 485 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5425
GET https://conductscience.org/api/genes/v1/5425/patents?page=2